➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKesson
Johnson and Johnson
AstraZeneca
Express Scripts

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,098,892

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,098,892
Title:Solid dosage formulations of an orexin receptor antagonist
Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer. A concentration-enhancing polymer is water soluble or readily disperse in water, so that when the polymer is placed in water or an aqueous environment (e.g. fluids in the gastrointestinal (GI) tract or simulated GI fluids), the solubility and/or bioavailability of suvorexant is increased over the solubility or bioavailability in the absence of the polymer.
Inventor(s): Harmon; Paul A. (Audubon, PA), Variankaval; Narayan (Plainsboro, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:14/404,147
Patent Claims: 1. A pharmaceutical composition comprising: suvorexant in an amorphous form; and copovidone; wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and copovidone.

2. The pharmaceutical composition of claim 1, wherein the suvorexant is present in a form that contains at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

3. The pharmaceutical composition of claim 1, wherein the suvorexant is present in a form that contains at least 95 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

4. The pharmaceutical composition of claim 1, wherein the suvorexant is present in a form that contains at least 98 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

5. The pharmaceutical composition of claim 1, wherein the suvorexant is present in a form that contains at least 99 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition additionally comprises lactose.

7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition additionally comprises microcrystalline cellulose.

8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition additionally comprises croscarmellose sodium.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition additionally comprises magnesium stearate.

10. A pharmaceutical composition comprising: suvorexant in an amorphous form; copovidone; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; and magnesium stearate; wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and copovidone.

11. The pharmaceutical composition of claim 10, wherein the suvorexant is present in a form that contains at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

12. The pharmaceutical composition of claim 10, wherein the suvorexant is present in a form that contains at least 95 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

13. The pharmaceutical composition of claim 10, wherein the suvorexant is present in a form that contains at least 98 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

14. The pharmaceutical composition of claim 10, wherein the suvorexant is present in a form that contains at least 99 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.

15. The pharmaceutical composition of claim 11, which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.

16. The pharmaceutical composition of claim 12, which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.

17. The pharmaceutical composition of claim 13, which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.

18. The pharmaceutical composition of claim 14, which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Express Scripts
Baxter
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.